
Academic Journal
Q1Journal for ImmunoTherapy of Cancer
About Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer is a scholarly journal published by BMJ Publishing Group. SCImago 2025 lists it in Q1, with an SJR of 4.114 and H-index of 155.
Coverage: 2013-2026. Research categories: Cancer Research (Q1); Immunology (Q1); Immunology and Allergy (Q1); Molecular Medicine (Q1); Oncology (Q1); Pharmacology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Immunotherapy and Immune Responses; CAR-T cell therapy research; Immune Cell Function and Interaction; Immune cells in cancer; Monoclonal and Polyclonal Antibodies Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death
Jiaqian Li, Mingzhu Liu, Chunping Wei, Yunxuan Zhou et al.
2026-10 · DOI: 10.1136/jitc-2025-014506Propionate promotes CD8 + T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer
Jingying Pan, Le Tong, Rushan Fei, Kai Wu et al.
2026-10 · DOI: 10.1136/jitc-2026-015279Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A)
Pengxin Zhang, DaQuan Wang, Wenzhuo He, HongMei Zhang et al.
2026-10 · DOI: 10.1136/jitc-2026-016467PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy
Tung Nguyen Thanh Uong, Meesun Yoon, Nhat Phuoc Nguong Minh Nguyen, Mijeong Lee et al.
2026-10 · DOI: 10.1136/jitc-2026-016896Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0
Nirali N Shah, Charles Craddock, Lia Gore, Monica L Guzman et al.
2026-09 · DOI: 10.1136/jitc-2026-015963IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8 + T cells while restraining regulatory T-cell accumulation
Kathryn M LaPorte, Janika Põder, Daria Ivanova, Molly Dalzell et al.
2026-09 · DOI: 10.1136/jitc-2026-015104Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors
Ecaterina E Dumbrava, Do-Youn Oh, Min-Hee Ryu, Emiliano Calvo et al.
2026-09 · DOI: 10.1136/jitc-2025-014309Epigenetic plus cytokine therapy induces stem-like CD8 + T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance
Christine Mall Minnar, Masaya Miyamoto, Asma Sarah Khelifa, Grace Lui et al.
2026-09 · DOI: 10.1136/jitc-2026-015228HIF1A + CSF3R + neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC
Yaoyao Zhou, Ziyun Liu, Parhat Kaysar, Yuxi Han et al.
2026-09 · DOI: 10.1136/jitc-2026-014772Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer
Wenxin Lian, Hui Yang, Yuqi Zhang, Chenchen Liu et al.
2026-09 · DOI: 10.1136/jitc-2026-015037Normal-immunopeptidome denominator: a safety atlas for immunotherapies targeting non-canonical and aberrantly expressed tumor antigens
Li-zhen Chen
2026-09 · DOI: 10.1136/jitc-2026-016056CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers
Xiumei Che, Un-Jung Yun, Junsub Lee, Hyun-Hee Koh et al.
2026-09 · DOI: 10.1136/jitc-2025-014131IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4 + T-cell responses
Yu Guo, Meng Wang, Yujing Xuan, Lvla Pan et al.
2026-09 · DOI: 10.1136/jitc-2026-016326CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer
Amgad Muneer, Eman Showkatian, Yuliya Kitsel, Maliazurina B Saad et al.
2026-09 · DOI: 10.1136/jitc-2026-015014NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma
Yan Li, Xiaomei Zhuang, Yisen Tang, Wanhua Feng et al.
2026-09 · DOI: 10.1136/jitc-2026-015639PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy
Sanam Shafaattalab, Alexander Partin, Aaron Winters, Richele Bruno et al.
2026-09 · DOI: 10.1136/jitc-2026-015068METLUNG: plasma metabolomic profiling identifies metabolomic signatures associated with immunotherapy outcomes in non-small cell lung cancer
Clara Lucía-Gozálvez, Christopher Papandreou, Joan Badia, Raquel Cumeras et al.
2026-09 · DOI: 10.1136/jitc-2026-016077Screening of known gut microbiome-derived metabolites in anti-tumor immunity of colorectal cancer
Xinan Zhang, Zixuan Li, Hui Hua, Hao Song et al.
2026-09 · DOI: 10.1136/jitc-2026-015554Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL
Kexin Wang, Leijin Yu, Xinghua Liang, Fengmei Song et al.
2026-09 · DOI: 10.1136/jitc-2026-015196Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity
Franklin Ning, Emily San Andres-Montalvan, Thomas J Meyer, Sabina Kaczanowska et al.
2026-09 · DOI: 10.1136/jitc-2026-014938Reviews
Community Reviews
Version History
September 11, 2026 at 10:15 am
September 11, 2026